Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Characterization of Patients with aHUS and Triggering/Associated Events, with and without Complement Pathogenic Variants or Anti-Cfh Antibodies: A Global aHUS Registry Analysis

Andrew Siedlecki, Imad Al-Dakkak, Katerina Anokhina, Nicole Isbel, Véronique Frémeaux-Bacchi, Rodney Gilbert, Laurence Greenbaum, Gema Ariceta, Gianluigi Ardissino, Franz Schaefer, Eric Rondeau, Christoph Licht

Blood (2022) 140 (Supplement 1): 2767–2769.

https://doi.org/10.1182/blood-2022-155814

Published: 2022

Journal Articles

The Complement System Mediates COVID-19 Endothelial Cell Injury, Modifying Cell Permeability

Arlette Bohorquez, NIyousha Rostam, Carolina Ortiz-Sandoval, Claire Howard, Walter H.A. Kahr, Christopher J. Campbell, Christoph Licht

Blood (2022) 140 (Supplement 1): 2665–2666.

https://doi.org/10.1182/blood-2022-169506

Published: 2022

Journal Articles

Pediatric Sickle Cell Disease: A Potential Role for the Complement System

Daniel Diatlov, Arlette Bohorquez, Melanie Jackson, Melina Cheong, Walter H.A. Kahr, Kevin H.M. Kuo, Melanie Kirby-Allen, Christoph Licht

Blood (2022) 140 (Supplement 1): 2517–2518.

https://doi.org/10.1182/blood-2022-167696

Published: 2022

Journal Articles

Peripheral Venous Access for Collection of Immune Effector Cells and Hematopoietic Stem Cells Is Feasible and Safe in Older Children and Young Adult Patients

Joel Livingston, MDMSc, Maria Di-Mola, RN, Jane Lowry, RN, Nigel Ruse, RN, Christoph Licht, MDFRCP, Muhammad Ali, Tal Schechter-Finkelstein, MD, KY Chiang, Joerg Krueger, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137747

Published: 2020

Journal Articles

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

Laurence A. Greenbaum, MDPhD, Yahsou Delmas, MD PhD, Fadi Fakhouri, MD PhD, John F. Kincaid, MD MA, Christoph Licht, MD FRCP(C), FASN, Enrico E. Minetti, MD, Chris Mix, MD, Francois Provôt, MD, Eric Rondeau, MD PhD, Neil Sheerin, BSc, MBBS, MRCP, PhD FRCP, Jimmy Wang, PhD, Laurent E. Weekers, MD, Jan Menne, MD

Blood (2015) 126 (23): 2252.

https://doi.org/10.1182/blood.V126.23.2252.2252

Published: 2015

Journal Articles

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Christoph Licht, MD FRCP(C), FASN, Gianluigi Ardissino, MD PhD, Gema Ariceta, MD PhD, David J. Cohen, MD, Christoph Gasteyger, MD, Laurence A. Greenbaum, MDPhD, Masayo Ogawa, MD FAAP, Varant Kupelian, PhD, Franz Schaefer, MD, Johan Vande Walle, MD PhD, Véronique Frémeaux-Bacchi, MD PhD

Blood (2015) 126 (23): 4640.

https://doi.org/10.1182/blood.V126.23.4640.4640

Published: 2015

Journal Articles

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Laurence A. Greenbaum, MDPhD, Marc Fila, MD PhD, Gianluigi Ardissino, MD PhD, Samhar I. Al-Akash, MD, Jonathan H Evans, MD, Kenneth Lieberman, MD, Silvio Maringhini, MD, Lars Pape, MD, Lesley Rees, MD FRCPCH, Nicole C.A.J. van de Kar, MD PhD, Johan Vande Walle, MD PhD, Masayo Ogawa, MD FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4986.

https://doi.org/10.1182/blood.V124.21.4986.4986

Published: 2014

Journal Articles

Utility of Complement and ADAMTS13 Testing in Diagnosis of Thrombotic Microangiopathy: A Single Centre Retrospective Review

Katerina Pavenski, MD FRCP, Christoph Licht, MD, Michael Kirschfink

Blood (2014) 124 (21): 2787.

https://doi.org/10.1182/blood.V124.21.2787.2787

Published: 2014

Journal Articles

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Katerina Pavenski, MD FRCP, Jerome M. Teitel, MD, Gloria Lim, BSc, MSc, MD, Michelle Sholzberg, MD, Michael Kirschfink, Christoph Licht, MD FRCP(C), FASN

Blood (2014) 124 (21): 4186.

https://doi.org/10.1182/blood.V124.21.4186.4186

Published: 2014

Journal Articles

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Christoph Licht, MD FRCP(C), FASN, Gianluigi Ardissino, MD PhD, Gema Ariceta, MD PhD, David Cohen, MD, Christoph Gasteyger, MD, Laurence A. Greenbaum, MDPhD, Masayo Ogawa, MD FAAP, Franz Schaefer, MD, Johan Vande Walle, MD PhD, Veronique Fremeaux-Bacchi, MD PhD

Blood (2014) 124 (21): 4204.

https://doi.org/10.1182/blood.V124.21.4204.4204

Published: 2014

Journal Articles

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, Yahsou Delmas, MD, Maria Herthelius, MD, Camille L. Bedrosian, MD, Chantel Loirat

Blood (2013) 122 (21): 2186.

https://doi.org/10.1182/blood.V122.21.2186.2186

Published: 2013

Journal Articles

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Larry Greenbaum, MD, Marc Fila, Gianluigi Ardissino, Samhar Al-Akash, Jonathan Evans, Paul Henning, Kenneth Lieberman, Silvio Maringhini, Lars Pape, Lesley Rees, Nicole Kar, Johan Vande Walle, Masayo Ogawa, MD, FAAP, Camille L. Bedrosian, MD, Christoph Licht, MD

Blood (2013) 122 (21): 2191.

https://doi.org/10.1182/blood.V122.21.2191.2191

Published: 2013

Journal Articles

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy

Sonata Jodele, Christoph Licht, Jens Goebel, Bradley P. Dixon, Kejian Zhang, Theru A. Sivakumaran, Stella M. Davies, Fred G. Pluthero, Lily Lu, Benjamin L. Laskin

Blood (2013) 122 (12): 2003–2007.

https://doi.org/10.1182/blood-2013-05-501445

Published: 2013

Journal Articles

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Samhar I. Al-Akash, Timothy H. J. Goodship, MD, Richard J. H. Smith, MD, Christophe M. Legendre, MD, Christoph Licht, MD, Petra Muus, MD, PhD, Camille L. Bedrosian, MD, Veronique Frémeaux-Bacchi, PhD, Chantal Loirat, MD

Blood (2012) 120 (21): 2085.

https://doi.org/10.1182/blood.V120.21.2085.2085

Published: 2012

Journal Articles

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe M. Legendre, MD, Kenneth W. Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L. Bedrosian, MD, Chantal Loirat, MD

Blood (2012) 120 (21): 985.

https://doi.org/10.1182/blood.V120.21.985.985

Published: 2012

Journal Articles

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Petra Muus, MD, PhD, Christoph Licht, MD, Tim H. J. Goodship, MD, Larry Greenbaum, MD, Camille L Bedrosian, MD, Chantal Loirat, MD, Christophe Legendre, MD

Blood (2011) 118 (21): 4772.

https://doi.org/10.1182/blood.V118.21.4772.4772

Published: 2011

Journal Articles

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Christoph Licht, MD, Petra Muus, MD, PhD, Christophe Legendre, MD, Kenneth W Douglas, MD, Maryvonne Hourmant, MD, Yahsou Delmas, MD, Maria Herthelius, MD, Antonella Trivelli, MD, Timothy H. J. Goodship, MD, Camille L Bedrosian, MD, Chantal Loirat, MD

Blood (2011) 118 (21): 3303.

https://doi.org/10.1182/blood.V118.21.3303.3303

Published: 2011

Journal Articles

Platelet-associated complement factor H in healthy persons and patients with atypical HUS

Christoph Licht, Fred G. Pluthero, Ling Li, Hilary Christensen, Sandra Habbig, Bernd Hoppe, Denis F. Geary, Peter F. Zipfel, Walter H. A. Kahr

Blood (2009) 114 (20): 4538–4545.

https://doi.org/10.1182/blood-2009-03-205096

Published: 2009

Journal Articles

Complement Factor H in Human Platelets: Implications for Atypical HUS.

Walter H.A. Kahr, MD, PhD, Fred G Pluthero, PhD, Christoph Licht, MD

Blood (2008) 112 (11): 1833.

https://doi.org/10.1182/blood.V112.11.1833.1833

Published: 2008

Journal Articles

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency

Mihály Józsi, Christoph Licht, Stefanie Strobel, Svante L. H. Zipfel, Heiko Richter, Stefan Heinen, Peter F. Zipfel, Christine Skerka

Blood (2008) 111 (3): 1512–1514.

https://doi.org/10.1182/blood-2007-09-109876

Published: 2008

Includes: Supplemental data

NARROW

Characterization of Patients with aHUS and Triggering/Associated Events, with and without Complement Pathogenic Variants or Anti-Cfh Antibodies: A Global aHUS Registry Analysis

The Complement System Mediates COVID-19 Endothelial Cell Injury, Modifying Cell Permeability

Pediatric Sickle Cell Disease: A Potential Role for the Complement System

Peripheral Venous Access for Collection of Immune Effector Cells and Hematopoietic Stem Cells Is Feasible and Safe in Older Children and Young Adult Patients

Eculizumab Prevents Thrombotic Microangiopathy: Long-Term Follow-up Study of Patients with Atypical Hemolytic Uremic Syndrome

The Global aHUS Registry: Characteristics of 826 Patients with Atypical Hemolytic Uremic Syndrome

Eculizumab Inhibits Thrombotic Microangiopathy and Improves Renal Function in Pediatric Patients with Atypical Hemolytic Uremic Syndrome: 1-Year Update

Utility of Complement and ADAMTS13 Testing in Diagnosis of Thrombotic Microangiopathy: A Single Centre Retrospective Review

Genotype Phenotype Correlation in Patients with aHUS and Abnormal Genetic Studies: A Single Centre Experience

Baseline Demographics and Characteristics of 466 Patients with Atypical Hemolytic Uremic Syndrome in the Global aHUS Registry

Time To Hematologic and Renal Improvements In Atypical Hemolytic Uremic Syndrome Patients With Long Disease Duration and Chronic Kidney Disease (CKD) Treated With Eculizumab

Eculizumab (ECU) Inhibits Thrombotic Microangiopathy (TMA) and Improves Renal Function In Pediatric Patients (Pts) With Atypical Hemolytic Uremic Syndrome (aHUS)

Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy

Eculizumab Is an Effective Treatment for Atypical Hemolytic Uremic Syndrome in Patients with or without Identified Genetic Complement Mutations or Complement Factor H Auto-Antibodies.

Eculizumab (ECU) Safety and Efficacy in Atypical Hemolytic Uremic Syndrome (aHUS) Patients with Long Disease Duration and Chronic Kidney Disease (CKD): 2-Year Results

Eculizumab (ECU) Significantly Improves Health-Related Quality of Life (HRQoL) in Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

Eculizumab Is An Effective Long-Term Treatment In Patients with Atypical Hemolytic Uremic Syndrome (aHUS) Previously Receiving Chronic Plasma Exchange/Infusion (PE/PI): Extension Study Results,

Platelet-associated complement factor H in healthy persons and patients with atypical HUS

Complement Factor H in Human Platelets: Implications for Atypical HUS.

Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only